RCM
CYTK icon

Raleigh Capital Management’s Cytokinetics CYTK Stock Holding History

Raleigh Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-13
Closed -$430 – 573
2025
Q2 		$430 Hold
13
– – ﹤0.01% 494
2025
Q1 		$522 Buy
+13
New +$597 ﹤0.01% 480

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Raleigh Capital Management's CYTK Position: Q3 2025 in Review

Raleigh Capital Management sold out of Cytokinetics (CYTK) in Q3 2025, closing a stake of 13 shares — an estimated $430 sold.

Raleigh Capital Management first reported a position in CYTK in Q1 2025 and held it in 2 quarters. The position peaked at $522 in Q1 2025. 380 funds tracked by Wall St. Rank hold CYTK as of Q3 2025.

  • Raleigh Capital Management reported no remaining Cytokinetics position as of Q3 2025 after selling out during the quarter.
  • Raleigh Capital Management sold 13 Cytokinetics shares in Q3 2025, an estimated $430.
  • Raleigh Capital Management first reported a position in Cytokinetics in Q1 2025 and held it in 2 quarters.
  • Raleigh Capital Management's Cytokinetics position peaked at $522 in Q1 2025.
  • 380 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2025.

Based on Raleigh Capital Management's 13F filing for Q3 2025, filed 4 Nov 2025.